Elevated Serum IgG4 Defines Specific Clinical Phenotype of Rheumatoid Arthritis

Table 1

Baseline demographic characteristics of all RA patients and untreated RA patients.

Characteristics	All patients	Untreated patients
	Age, years	(19~86)	(29~81)
Gender, (%) female	85 (62.5)	24 (58.5)
Disease duration, months	(1~360)	(1~264)
28TJC	(0~28)	(0~28)
28SJC	(0~26)	(0~24)
HAQ score	(0.0~3.0)	(0.0~3.0)
PtGA	(0~10)	(1~10)
PrGA	(0~10)	(1~10)
Pain VAS	(0~10)	(0~10)
CRP, mg/L	(0.2~228)	(1~149)
ESR, mm/h	(1~148)	(1~148)
IgE, IU/mL	(4~13300)	(5~13300)
Eosinophils, 10^9/L	(0.0~0.9)	(0.0~0.6)
RF, IU/mL	(10~2940)	(10~2590)
Anti-CCP Ab, U/mL	(2~805)	(2~805)
DAS28(4)-CRP	(1.0~8.2)	(2.4~7.7)
Medications before enrollment
Prednisone	72 (52.9)	—
Methotrexate	60 (44.1)	—
Leflunomide	47 (34.6)	—
Sulfasalazine	12 (8.8)	—
Hydroxychloroquine	17 (12.5)	—
Cyclosporine	1 (0.7)	—
TNF-α antagonist	16 (11.8)	—

Data were described with mean ± standard deviation (range) or number (percentage) unless stated otherwise.
28TJC: 28 tender joint counts; 28SJC: 28 swollen joint counts; HAQ: Health Assessment Questionnaire; PtGA: patient global assessment of disease activity; PrGA: provider global assessment of disease activity; VAS: visual analog scales; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; anti-CCP Ab: anticyclic citrullinated peptide antibody; DAS28: Disease Activity Score with 28-joint counts.
Two (1.5%) patients had received treatment of infliximab, 14 (10.3%) patients had received treatment of Recombinant Human Tumor Necrosis Factor-α Receptor I: IgG Fc Fusion Protein for Injection.